 | |
| Company type | Limited liability company |
|---|---|
| Industry | |
| Founded | 2005 in Moscow |
| Founders | Petr Bely |
| Headquarters | Moscow , Russia |
Area served | Russia & Worldwide [1] |
Key people | Petr Bely (CEO) |
| Products | Pharmaceutical drugs |
| Website | promomed |
Promomed Group is a Russian pharmaceutical company specialising in elaboration, production, check studies and distribution of medicinal drugs. Its major production site, the Biokhimik Plant, is in Saransk.
The Promomed Group was established in 2005. It was planned, from the outset, that the company would be carrying out clinical trials as well as exercising promotional marketing of pharmaceuticals made to order. [2] as its first pharmaceutical drug. [2]
In 2007, the company launched Reduxin, a drug to treat obesity. [3]
In 2012, the Promomed Group, in cooperation with National Medical Research Center for Endocrinology (Russia) and Russian Association of Endocrinologists, initiated a world's largest observational study that covered 100 000 patients and 3 000 doctors in 142 locations around Russia. [4] [5]
In 2015, Promomed acquired the Biokhimik plant; that same year an updated work unit got underway at the plant, to produce lozenges and capsules. [6] [7] [8]
Still in 2017 and for the first time in Russia, full-cycle production, from a strain variant to the finished product, of an antibiotic substance, Vancomycin, was developed and put in working order. [9]
In 2018, the Company opened its Representative office in Vietnam. [10]
In 2020, Promomed Group obtained approval for production and marketing of areplivir, a drug developed on the basis of favipiravir molecule for the treatment of COVID-19. [11] [12] That same year, the Company placed its bonds on the Moscow Exchange, with a total value of 1 billion rubles (next placements in 2021 - 5 billion rubles and in 2022 - 2,5 billion rubles). [13] [14] [15] [16]
In February 2022, Ministry of Health of the Russian Federation granted marketing authorisation, to Promomed, for Esperavir, a drug based on molnupiravir and developed for the treatment of COVID-19. [17] [18]
In April 2022, Ministry of Health of the Russian Federation approved yet another medication produced by Promomed, an anti-COVID drug, Skyvira. [19]
In 2023, Promomed Group bought a controlling stake in pharmaceutical company Berakhim. [20]
In June 2023, at the time of the 26th St. Petersburg International Economic Forum, an agreement between the Government of Moscow and the Promomed Group was signed, respectively, by Vladislav Ovchinsky, Head of the Investments and Industries Policy Department of the Government of Moscow, and Petr Bely, Chair of the Board of Directors of the Promomed Group, on the establishment of a research centre at the Pechatniki site and of a facility for manufacturing of biotechnological products at the Alabushevo site, of the Technopolis Moscow Special Economic Zone (SEZ). [21] [22]
Promomed Group is engaged in production of endocrinological, rheumatological, neurological, antiviral, antibacterial, antitumor and other types of drugs. [23] [4]
The company's portfolio contained over 180 various names of drugs in 2021 and 80 percent of them were on the official List of vital medicines (the list of medicines approved by the Government of the Russian Federation for the purpose of state regulation of prices for medicines). [2] [24] By 2023, the portfolio expanded up to 250 names of drugs while the share of vital medicines in it remained at 80 percen. [20]
The Group produces medicines at a large Biochemist enterprise in Saransk. A small part of the drugs (including areplivir) were also produced in 2021 at the facilities of Ozon LLC. [25]
In summer of 2023, the Promomed Group signed an agreement with the Government of Moscow to establish production of cutting-edge pharmaceuticals, including drugs under import substitution industrialisation policy, within the framework of the Technopolis Moscow Special Economic Zone (SEZ). Its experimental production unit is expected to make about 250 thousand medicine bottles a year, at its initial stage. [21]
The Group has adopted its own ESG strategy and it is being implemented. In October 2022, Promomed Group published its first ever ESG report (environmental, social, and corporate governance). [26] [27]
Petr Bely — founder and principal shareholder of Promomed Group, chair of the board of directors. [28]
In 1994, with the support of today's subsidiary Promomed, JSC Biokhimik, the Biokhimik-Mordovia football club was created, which existed until 2004 and in 2005 was transformed into the FC Mordovia Saransk. [29]
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and a Union Army veteran of the American Civil War.
The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.
The Siberian State Medical University, SibMed is a public medical school in Tomsk, Russia. It was founded in May, 1878 by the decree of the Emperor Alexander II. Today, Siberian State Medical University provides undergraduate, graduate, and postgraduate degrees in biochemistry, biophysics, general medicine, pediatrics, dentistry, pharmacy, and nursery fields. It is one of the few universities in Russia that has its own hospital that is not only providing medical care for citizens in Tomsk Region and other regions but, also, is a training center for students and medical professionals. It has more than 6 500 students that come from 39 countries worldwide. In 2017, SibMed obtained the status of the only flagship medical university in Russia.
Beximco Pharmaceuticals Ltd, also known as Beximco Pharma, is a pharmaceutical company in Bangladesh. It is a part of Bangladesh Export Import Company Limited (BEXIMCO).
Rusnano Group is a Russian state-established and funded company. The Rusnano Group's mission is to create competitive nanotechnology-based industry in Russia. Rusnano invests directly and through indirect funds into all major knowledge-based areas where nanotechnology is widely implemented: electronics, optics, telecom, classic and renewable energy, healthcare and biotechnology, materials and metallurgy, engineering and chemistry.
The situation with the spread of HIV/AIDS in Russia is described by some researchers as an epidemic. The first cases of human immunodeficiency virus infection were recorded in the USSR in 1985-1987. Patient zero is officially considered to be a military interpreter who worked in Tanzania in the early 1980s and was infected by a local man during sexual contact. After 1988—1989 Elista HIV outbreak, the disease became known to the general public and the first AIDS centers were established. In 1995-1996, the virus spread among injecting drug users (IDUs) and soon expanded throughout the country. By 2006, HIV had spread beyond the vulnerable IDU group, endangering their heterosexual partners and potentially the entire population.
Alabuga is a special economic zone of an industrial and production type located in a 20 km² area in the Yelabuzhsky District of the Republic of Tatarstan in the Kama Innovative Territorial Production Cluster 10 km from Yelabuga, 25 km from Naberezhnye Chelny, 40 km from Nizhnekamsk and 210 km from the regional center — Kazan. The shareholders of the management company of the SEZ "Alabuga" are the Russian Federation through the JSC "Special Economic Zones" with 100% state participation.
Magnit is one of Russia's largest food retailers. It was founded in 1994 in Krasnodar by Sergey Galitsky. As of March 2016, the company had 12,434 stores in 2,385 locations. They include 9,715 convenience stores, 225 hypermarkets, 2,337 Magnit Cosmetics stores and 157 Magnit family stores. The company employs more than 140,000 people and has been opening several dozen stores each month.
TransContainer is a Russian transportation company, Russia's largest railway container operator. The Company provides a full range of transportation and logistics services in integration with other assets of Delo Group. It is Russia's main intermodal container transport and integrated logistics company; it transports over a million TEUs per year.
Microgen is Russia's largest producer of immunobiological products, one of the three largest pharmaceutical companies in Russia.
Alexander Semenovich Vinokurov is a Russian businessman. He is one of the main owners of the privately held investment company Marathon Group and the largest shareholder of retailer Magnit. Vinokurov was added to the EU Sanctions List on 9 March 2022 for providing a substantial source of revenue to the government of the Russian Federation during the Russo-Ukrainian War.
The COVID-19 pandemic in Russia was a part of the ongoing pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2.
Molnupiravir, sold under the brand name Lagevrio, is an antiviral medication that inhibits the replication of certain RNA viruses. It is used to treat COVID‑19 in those infected by SARS-CoV-2. It is taken by mouth.
R-Pharm is an international pharmaceutical company headquartered in Russia. It reached the headlines in September 2020 following approval of its drug "Coronavir" as a treatment in cases of mild to moderate COVID-19 infection. It was founded by Alexey Repik in 2001, but has had an increasingly international operations base since, with Japanese Corporation Mitsui & Co., Ltd. acquiring 10% of its shares in 2017.
The COVID-19 vaccination campaign in Russia is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Russia became the first country to begin a mass COVID-19 vaccination programme on 5 December 2020, starting with primarily doctors, medical workers and teachers. In January 2021, this was extended to the entire population.
Sovcombank is a Russian privately owned universal bank included in the list of 13 systemically important Russian banks. In terms of assets, it ranks 9th among Russian banks.
The Service-Telecom Group of Companies is an independent wireless telecommunication infrastructure operator that constructs and leases antenna-mast structures (AMS) to place telecom equipment.
